Tanaka Shin, Yokoi Tadashi, Katagiri Satoshi, Yoshida Tomoyo, Nishina Sachiko, Azuma Noriyuki
Department of Ophthalmology and Laboratory for Visual Science, National Center for Child Health and Development, Tokyo, Japan .
Retin Cases Brief Rep. 2021 Nov 1;15(6):772-777. doi: 10.1097/ICB.0000000000000887.
To describe the clinical features of severe recurrent fibrovascular proliferation after intravitreal bevacizumab injections and laser photocoagulation for aggressive posterior retinopathy of prematurity.
This retrospective, nonrandomized case series reviewed the medical and ophthalmic records in the referral hospital and our hospital.
Four patients (seven eyes) with aggressive posterior retinopathy of prematurity.
The patients were referred for vitrectomy with/without lensectomy for recurrent fibrovascular proliferation with a tractional retinal detachment after combined intravitreal bevacizumab injections and laser photocoagulation. Three patients were born at 22 weeks or 23 weeks' gestational age and one patient at 29 weeks' gestational age. Preoperatively, fluorescein angiography images showed all eyes had tractional retinal detachment from regrowth of fibrovascular proliferation 3 months to 5 months after the intravitreal bevacizumab injection and abnormal retinal vasculature; four eyes had a broad ischemic retina. Postoperatively, four eyes had retinal attachment and three eyes a total retinal detachment. Neovascular glaucoma developed in five of the seven eyes during the clinical course.
Severe fibrovascular proliferation may recur due to widespread retinal ischemia with capillary dropout and abnormal vasculature after failed combined intravitreal bevacizumab and laser photocoagulation therapy as the initial treatment for aggressive posterior retinopathy of prematurity. Careful follow-up is important especially after anti-vascular endothelial growth factor treatment, with recognition that severe reactivation is possible.
描述玻璃体内注射贝伐单抗联合激光光凝治疗侵袭性早产儿视网膜病变后严重复发性纤维血管增殖的临床特征。
本回顾性、非随机病例系列研究回顾了转诊医院和我院的医学及眼科记录。
4例(7只眼)侵袭性早产儿视网膜病变患者。
患者因玻璃体内注射贝伐单抗联合激光光凝后复发性纤维血管增殖伴牵引性视网膜脱离而转诊行玻璃体切除术(伴或不伴晶状体切除术)。3例患者孕周为22周或23周,1例患者孕周为29周。术前,荧光素血管造影图像显示,所有患眼在玻璃体内注射贝伐单抗后3个月至5个月因纤维血管增殖再生长出现牵引性视网膜脱离及视网膜血管异常;4只眼存在广泛的视网膜缺血。术后,4只眼视网膜复位,3只眼完全视网膜脱离。7只眼中有5只眼在病程中发生了新生血管性青光眼。
作为侵袭性早产儿视网膜病变的初始治疗,玻璃体内注射贝伐单抗联合激光光凝治疗失败后,由于广泛的视网膜缺血伴毛细血管闭塞和血管异常,严重的纤维血管增殖可能复发。尤其是在抗血管内皮生长因子治疗后,仔细的随访很重要,因为要认识到严重复发是可能的。